Last Updated on November 4, 2021 by The Health Master
New Delhi: Sun Pharmaceutical Industries announced the availability of Winlevi cream, used for the treatment of acne vulgaris in patients 12 years and older, in the US market.
A first-in-class topical androgen receptor inhibitor, Winlevi was approved by the US Food and Drug Administration (USFDA) in August 2020.
Winlevi is the first USFDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years, Sun Pharma said in a statement.
It works by inhibiting the effects of androgen receptors in cells of the sebaceous glands (oil producing glands in the skin) to help reduce sebum (oil) production and inflammation.
It is suitable for both males and females.
“The US launch of WINLEVI enhances Sun Pharma’s specialty product portfolio and reflects our commitment to meeting patients’ needs by providing innovative dermatology medicines,” Sun Pharma CEO (North America) Abhay Gandhi said.
With its safety and tolerability profile, combined with its demonstrated efficacy in clinical trials, Winlevi has the potential to be an important topical treatment option for the millions of Americans affected by acne vulgaris, he added.
The most prevalent skin condition in the US, acne affects up to 50 million Americans annually, the company said citing data.
Prior to the availability of Winlevi, conventional topical approaches to acne treatment focused on either addressing follicular hyperkeratinisation, reducing inflammation, or exerting antibacterial effects.
In August this year, Sun Pharma and specialty pharma firm Cassiopea SpA had inked an exclusive licence and supply agreements for Winlevi cream.
As per the pact, Sun Pharma has the exclusive right to commercialise Winlevi in the US and Canada. Cassiopea is the exclusive supplier of the product.
Dr Reddy’s Labs launches generic Ephedrine Sulfate injection
Sun Pharma launches drug to treat Plaque Psoriasis in Canada
Glenmark launches unique fixed dose combination drug for Diabetes
AstraZeneca launches Clinical Trial Data division in India
MSN Labs launches Empagliflozin tablets for diabetes in India
Intas launches the World’s first SB-100mg Itraconazole
Duties of Retail Chemists / Medical Store / Pharmacy
Govt to plan to conduct these 8 studies on Pharma & Medical Devices
Pharma Industry urges NPPA to invoke Para 19 of DPCO 2013
Dr Reddy’s Labs launches generic Ephedrine Sulfate injection
Novartis gets USFDA approval for drug to treat Chronic Leukemia
Govt to amend New Drugs & Clinical Trials Rules
Govt takes important decisions on Pharma & Medical Devices Industry
Govt issued notification for Form 29: License to Mfg drugs for…
NFI 2021: Salient features of 6th Edition of National Formulary of India
Govt releases draft policy for R&D, Pharma and Medical Devices
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
